Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Williams RE, Kalilani L, DiBenedetti D, Zhou X, Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007 Nov 1;58(2007):348-58.
Appt SE, Clarkson TB, Lees CJ, Anthony MS. Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas. 2006 Sep 20;55(2):187-94.
Clarkson TB, Anthony MS, Cline JM, Lees CJ, Ederveen AG. Multisystem evaluations of the long-term effects of tibolone on postmenopausal monkeys. Maturitas. 2004 Aug 30;48(Suppl 1):24-9. doi: 10.1016/j.maturitas.2004.02.011
Johannes CB, Avis NA. Gender differences in sexual activity among mid-aged adults in Massachusetts. Maturitas. 1997 Apr;26(3):175-84.